Fig. 3.

Changes in expression of IFN-α receptor 1 (IFNAR1) and phosphorylation of TYK2 and JAK1 after IL-17A pretreatment. A, B HepG2-HBV1.3 cells were pretreated with or without 50 ng/ml IL-17A for 24 h, followed by co-treatment with or without 1000 IU/ml IFN-α for 24 or 48 h. Total cellular RNA was extracted for detection of IFNAR1 mRNA by RT-qPCR (A), and cell lysates were prepared for assay of IFNAR1 protein by western blotting (B). Relative expression of mRNA or protein was shown as fold-change compared to the mock-treated cells. C HepG2-HBV1.3 cells were pretreated with or without 50 ng/ml IL-17A for 24 h, followed by co-treatment with or without 1000 IU/ml IFN-α for 30 min, 6 h or 24 h. Whole cell lysates were collected for assay of phosphorylation of TYK2 and JAK1 by western blotting. Relative expression in group of IL-17A pretreatment was shown as fold-change compared to its corresponding IFN-α group at each timepoint. All data were shown as mean ± standard deviation (SD) (error bars) from at least 3 independent experiments. p < 0.05 is considered statistically significant. *p < 0.05, **p < 0.01 between two indicated groups